Multicenter, Randomized, Parallel Group Study to Compare the Incidence of Tocilizumab Related Infusion Reactions in Patients With Moderate to Severe Active RA, When Infusion is Given Over 31 Minutes Compared to 1 Hour
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms ACT-FAST
- Sponsors Roche
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned end date changed from 1 Jun 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 07 Nov 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).